Soligenix, Inc. (SNGX)
NASDAQ: SNGX · Real-Time Price · USD
1.610
-0.020 (-1.23%)
At close: Dec 5, 2025, 4:00 PM EST
1.640
+0.030 (1.86%)
After-hours: Dec 5, 2025, 7:54 PM EST
Soligenix Employees
As of December 31, 2024, Soligenix had 16 total employees, including 14 full-time and 2 part-time employees. The number of employees increased by 1 or 6.67% compared to the previous year.
Employees
16
Change (1Y)
1
Growth (1Y)
6.67%
Revenue / Employee
n/a
Profits / Employee
-$698,222
Market Cap
16.24M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SNGX News
- 3 days ago - Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space - GlobeNewsWire
- 17 days ago - Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma - PRNewsWire
- 4 weeks ago - Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results - PRNewsWire
- 7 weeks ago - Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma - PRNewsWire
- 2 months ago - Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma - PRNewsWire
- 2 months ago - Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma - PRNewsWire
- 2 months ago - Soligenix Announces Closing of $7.5 Million Public Offering - PRNewsWire
- 2 months ago - Soligenix Announces Pricing of $7.5 Million Public Offering - PRNewsWire